BioCentury
ARTICLE | Clinical News

Kyowa's KW-6356 improves motor symptoms in Phase IIa for early PD

August 31, 2018 6:24 PM UTC

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said low- and high-dose oral KW-6356 both improved motor symptoms compared with placebo in a Phase IIa trial in 168 patients with early Parkinson's disease who had not received other anti-Parkinson's drugs. Data were presented at the World Congress on Parkinson’s Disease and Related Disorders in Lyon.

On the double-blind, Japanese trial's primary endpoint, KW-6356 reduced Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS) part III motor symptom scores from baseline to week 12 by 5.37 points at the low dose and by 4.76 at the high dose vs. 3.14 points for placebo. KW-6356 was well tolerated...